The heterozygous NUDT15 variant is not associated with the severity of 6-mercaptopurine-related side effects in early intensification therapy for childhood acute lymphoblastic leukemia by Jimei Zhao, Masahiro Ueki, Saori Sawai, Minako Sugiyama, Yukayo Terashita, Shinsuke Hirabayashi, Yuko Cho, Ryoji Kobayashi, Yoichi Tanaka, Atsushi Manabe

“…Background: In the treatment of childhood acute lymphoblastic leukemia (ALL), 6-mercaptopurine (6-MP) is essential for early intensification and maintenance of therapy. …”
Get full text

Association of <i>NUDT15</i> c.415C>T and <i>FPGS</i> 2572C>T Variants with the Risk of Early Hematologic Toxicity During 6-MP and Low-Dose Methotrexate-Based Maintenance Therapy i... by Sunitha Kodidela, Patchava Dorababu, Dimpal N. Thakkar, Biswajit Dubashi, Rajan Sundaram, Niveditha Muralidharan, Ravi Prasad Nidanapu, Anil Aribandi, Suresh Chandra Pradhan, Chakradhara Rao Satyanarayana Uppugunduri

Subjects: Get full text

Redox-Responsive Coordination Polymers of Dopamine-Modified Hyaluronic Acid with Copper and 6-Mercaptopurine for Targeted Drug Delivery and Improvement of Anticancer Activity against Cancer Cells by Bo Tao, Zongning Yin

Subjects: Get full text

Cytostatic Drug 6-Mercaptopurine Degradation on Pilot Scale Reactors by Advanced Oxidation Processes: UV-C/H₂O₂ and UV-C/TiO₂/H₂O₂ Kinetics by Luis A. González-Burciaga, Juan C. García-Prieto, Manuel García-Roig, Ismael Lares-Asef, Cynthia M. Núñez-Núñez, José B. Proal-Nájera

Subjects: “…6-mercaptopurine photodegradation…”
Get full text

Cytotoxic profiles of a nanodrug delivery based on 6-mercaptopurine-coated magnetite-peg nanoparticles towards leukemia (WEHI-3B) cell lines by Dorniani, Dena, Kura, Aminu Umar, Fakurazi, Sharida, Hussein, Mohd Zobir

“…A drug active, 6-mercaptopurine (MP) was coated on the surface of Fe3O4-PEG nanoparticles using co-precipitation method in order to form a new magnetic nanocomposite (FPEGMP). …”
Get full text

Release behavior and toxicity profiles towards leukemia (WEHI-3B) cell lines 6-mercaptopurine-PEG-coated magnetite nanoparticles delivery systems by Dorniani, Dena, Kura, Aminu Umar, Hussein-Al-Ali, Samer Hasan, Hussein, Mohd Zobir, Fakurazi, Sharida, Shaari, Abdul Halim, Ahmad, Zalinah

“…The coating of an active drug, 6-mercaptopurine, into the iron oxide nanoparticles-polyethylene glycol (FNPs-PEG) in order to form a new nanocomposite, FPEGMP-2, was accomplished using coprecipitation technique. …”

Specific MRP4 Inhibitor Ceefourin-1 Enhances Apoptosis Induced by 6-Mercaptopurine in Jurkat Leukemic Cells, but Not in Normal Lymphoblast Cell Line CRL-1991 by Edgardo Becerra, Laura Berumen, Valeria Soto-Ontiveros, Guadalupe García-Alcocer

Subjects: “…6-mercaptopurine…”
Get full text

Preemptive <i>TPMT</i> Genotyping and Adherence to Genotype-Based Therapeutic Recommendations Reduces the Healthcare Cost in Patients Receiving Azathioprine or 6-Mercaptopurine for Autoimmune Diseases by Sarahí Valdez-Acosta, Pablo Zubiaur, Miguel Angel Casado, Jesús Novalbos, Ana Casajús, Diana Campodónico, Itziar Oyagüez, Francisco Abad-Santos

Get full text

Detection of Thiopurine S-Methyltransferase (TPMT) Polymorphisms TPMT*3A, TPMT*3B and TPMT*3C in Children with Acute Lymphoblastic Leukemia by Nawar S. Mohammed, Manal K. Rasheed, Hasanein H. Ghali, Shaymaa J. Ahmed 

Subjects: “…Acute Lymphoblastic Leukemia, 6-Mercaptopurine, Thiopurine S-methyltransferase, genetic polymorphisms.…”
Get full text

The Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment by Shoshana Rudin, Marcus Marable, R. Stephanie Huang

Subjects: Get full text

Mesoporous Silica Modified with Polydopamine and Zinc Ions as a Potential Carrier in the Controlled Release of Mercaptopurine by Mariusz Sandomierski, Martyna Chojnacka, Maria Długosz, Monika Pokora, Joanna Zwolińska, Łukasz Majchrzycki, Adam Voelkel

Subjects: Get full text

A Comprehensive Approach to Compatibility Testing Using Chromatographic, Thermal and Spectroscopic Techniques: Evaluation of Potential for a Monolayer Fixed-Dose Combination of 6-Mercaptopurine and Folic Acid by Edvin Brusač, Mario-Livio Jeličić, Matija Cvetnić, Daniela Amidžić Klarić, Biljana Nigović, Ana Mornar

Subjects: “…6-mercaptopurine…”
Get full text

Los polimorfismos de ITPA no predicen un riesgo adicional más allá de TPMT y NUDT15 para citopenia inducida por tiopurina en la enfermedad inflamatoria intestinal by A. Jena, N. Grover, P. Bhatia, M. Singh, D. Lad, K.K. Prasad, H. Singh, U. Dutta, V. Sharma

Subjects: Get full text

The Role of Pharmacogenetics in the Therapeutic Response to Thiopurines in the Treatment of Inflammatory Bowel Disease: A Systematic Review by Aline C. Ribeiro, Pâmela S. A. S. Gerheim, Julio Maria Fonseca Chebli, Jorge Willian L. Nascimento, Priscila de Faria Pinto

Subjects: Get full text

Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0–45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocol by Linea Natalie Toksvang, Bodil Als-Nielsen, Christopher Bacon, Ruta Bertasiute, Ximo Duarte, Gabriele Escherich, Elín Anna Helgadottir, Inga Rinvoll Johannsdottir, Ólafur G. Jónsson, Piotr Kozlowski, Cecilia Langenskjöld, Kristi Lepik, Riitta Niinimäki, Ulrik Malthe Overgaard, Mari Punab, Riikka Räty, Heidi Segers, Inge van der Sluis, Owen Patrick Smith, Marion Strullu, Goda Vaitkevičienė, Hilde Skuterud Wik, Mats Heyman, Kjeld Schmiegelow

Subjects: Get full text

Correction: Jamal et al. Preparation of 6-Mercaptopurine Loaded Liposomal Formulation for Enhanced Cytotoxic Response in Cancer Cells.... by Alam Jamal, Amer H. Asseri, Ehab M. M. Ali, Afnan H. El-Gowily, Mohamed Imran Khan, Salman Hosawi, Reem Alsolami, Tarek A. Ahmed

Get full text

Treatment of acute lymphocytic leukemia in Down syndrome by Yuki Gemma, Fumio Bessho, Hiroshi Yoshino

Subjects: Get full text

Polymorphisms of the <i>TPMT</i>, <i>NUDT15</i> genes and 6-mercaptopurine toxicity profile in adult patients with Ph-negative acute lymphoblastic leukemia/lymphomas on the ALL-2016 protocol by E. S. Kotova, O. A. Gavrilina, I. A. Yakutik, A. B. Sudarikov, Yu. A. Chabaeva, S. M. Kulikov, S. G. Beksaev, V. V. Troitskaya, G. A. Isinova, A. N. Sokolov, Z. T. Fidarova, I. A. Lukyanova, A. V. Abramova, V. N. Dvirnyk, I. V. Galtseva, T. N. Obukhova, E. N. Parovichnikova

Subjects: Get full text

Understanding interpatient variation of clinical responses among acute lymphoblastic leukaemia (All) patients treated with 6-mercaptopurine (6-Mp): a pharmacogenomics-metabolomics perspective / Wan Rosalina Wan Rosli by Wan Rosli, Wan Rosalina

“…This success is largely attributable to optimization of the use of chemotherapeutic agents such as 6-mercaptopurine (6-MP). However challenges still remain in striking a delicate balance between therapeutic outcome and risk of toxicity due to the narrow therapeutic window of anticancer drugs. …”
Get full text

A Limited Course of Eculizumab in a Child with the Atypical Hemolytic Uremic Syndrome and Pre-B Acute Lymphoblastic Leukemia on Maintenance Therapy: Case Report and Literature Revi... by Daniel Turudic, Danko Milosevic, Katarina Bilic, Zoltán Prohászka, Ernest Bilic

Subjects: Get full text